Novella Clinical, owned by Quintiles, struck a deal with the Cardiovascular Research Foundation to join forces on trial services, expanding their existing relationship to create a seamless offering for medical device developers.
At San Francisco's giant JP Morgan Healthcare Conference, tech company Qualcomm and Big Pharma player Novartis revealed a plan for a joint investment company with $100 million to spend on startups that "go beyond the pill."
Evotec, a risk-sharing R&D collaborator, has extended its relationship with biotech startup Padlock Therapeutics, inking a new deal that will see the pair progress into preclinical development.
Roche is shelling out $1 billion plus milestone payments for a majority share in Foundation Medicine, bolstering its diagnostics offerings for cancer and continuing its dealmaking streak.
X-Chem, a subsidiary of PPD, has signed a deal with Johnson & Johnson to provide its library of molecules to aid in the discovery of new treatments for inflammatory disease.
Roche is throwing the full weight of its global rep and more than a billion dollars behind Foundation Medicine's ambitious sequencing technology for guiding the personalized treatment of cancer as well as the development of new oncology meds. The pharma giant has wrapped a deal to buy up a majority stake in the molecular diagnostics company for $780 million at $50 a share--a premium rate that's more than twice Friday's close of $23.93.
After diving deep into the amyloid beta theory on Alzheimer's and coming up empty-handed--so far--Johnson & Johnson is partnering with Switzerland's AC Immune on an early-stage therapeutic vaccine that targets tau tangles as a prime suspect in triggering the memory-wasting ailment.
Incyte is jumping aboard Agenus' antibody discovery platform, signing up to partner on new immuno-oncology drugs with $60 million in cash and promises of up to $350 million in milestones. And the deal news quickly drove up Agenus' shares by more than 30% in premarket trading.
CardioFocus may be gearing up to file a PMA for its HeartLight catheter ablation system. Since the start of the New Year, the company has disclosed that it raised $32 million in a new financing and partnered with Japan Lifeline in an exclusive, multi-year Japan distribution agreement for HeartLight.
Hospira vowed to cut old product lines, address its production problems and invigorate innovation in its medical devices business as part of a grand plan revealed on May 1, 2013. Now it's making some progress as it said FDA had lifted an import alert that had prohibited import of infusion pump devices manufactured in its Costa Rica plant.